BETA-BLOCKERS AND ANGIOTENSIN CONVERSION ENZYME INHIBITORS FOR THE PREVENTION OF ANTHRACYCLINE-INDUCED CARDIOMYOPATHY: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Anthracycline-induced cardiomyopathy is a significant complication in anthracycline-treated cancer patients. There are emerging data that beta-blockers (BB) or angiotensin conversion enzyme inhibitors (ACEi) could be effective in preventing this complication. Medline and Embase were searched